Why the study?
Leaflet thrombosis after ViV-TAVI is emerging, but optimal management and anticoagulation strategies for THV thrombosis following ViV-TAVI remain unclear.
Leaflet thrombosis after ViV-TAVI is an important cause of THV degeneration that may present subclinically, highlighting the potential need for individualized prophylactic post-procedural oral anticoagulation.
No takes yet. Share an insight, caveat, or question.
Raises caution for antithrombotic regimens after ViV-TAVI; leaves open optimal individualized prophylaxis pending prospective data.
Aktuerk et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: